Literature DB >> 12384371

Tripeptide interference with human immunodeficiency virus type 1 morphogenesis.

Stefan Höglund1, Jin Su, Sara Sandin Reneby, Akos Végvári, Stellan Hjertén, Ida-Maria Sintorn, Hillary Foster, Yi-Pyng Wu, Ingela Nyström, Anders Vahlne.   

Abstract

Capsid assembly during virus replication is a potential target for antiviral therapy. The Gag polyprotein is the main structural component of retroviral particles, and in human immunodeficiency virus type 1 (HIV-1), it contains the sequences for the matrix, capsid, nucleocapsid, and several small polypeptides. Here, we report that at a concentration of 100 micro M, 7 of 83 tripeptide amides from the carboxyl-terminal sequence of the HIV-1 capsid protein p24 suppressed HIV-1 replication (>80%). The three most potent tripeptides, glycyl-prolyl-glycine-amide (GPG-NH(2)), alanyl-leucyl-glycine-amide (ALG-NH(2)), and arginyl-glutaminyl-glycine-amide (RQG-NH(2)), were found to interact with p24. With electron microscopy, disarranged core structures of HIV-1 progeny were extensively observed when the cells were treated with GPG-NH(2) and ALG-NH(2). Furthermore, nodular structures of approximately the same size as the broad end of HIV-1 conical capsids were observed at the plasma membranes of treated cells only, possibly indicating an arrest of the budding process. Corresponding tripeptides with nonamidated carboxyl termini were not biologically active and did not interact with p24.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12384371      PMCID: PMC128702          DOI: 10.1128/AAC.46.11.3597-3605.2002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  39 in total

1.  A novel basis of capsid stabilization by antiviral compounds.

Authors:  D K Phelps; C B Post
Journal:  J Mol Biol       Date:  1995-12-08       Impact factor: 5.469

2.  Crystal structure of human cyclophilin A bound to the amino-terminal domain of HIV-1 capsid.

Authors:  T R Gamble; F F Vajdos; S Yoo; D K Worthylake; M Houseweart; W I Sundquist; C P Hill
Journal:  Cell       Date:  1996-12-27       Impact factor: 41.582

3.  Functional domains of the capsid protein of human immunodeficiency virus type 1.

Authors:  T Dorfman; A Bukovsky; A Ohagen; S Höglund; H G Göttlinger
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

4.  Specific incorporation of cyclophilin A into HIV-1 virions.

Authors:  E K Franke; H E Yuan; J Luban
Journal:  Nature       Date:  1994-11-24       Impact factor: 49.962

5.  Assembly, processing, and infectivity of human immunodeficiency virus type 1 gag mutants.

Authors:  C T Wang; E Barklis
Journal:  J Virol       Date:  1993-07       Impact factor: 5.103

6.  Cyclophilin A is required for an early step in the life cycle of human immunodeficiency virus type 1 before the initiation of reverse transcription.

Authors:  D Braaten; E K Franke; J Luban
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

7.  Inhibition of infectious human immunodeficiency virus type 1 particle formation by Gag protein-derived peptides.

Authors:  M Niedrig; H R Gelderblom; G Pauli; J März; H Bickhard; H Wolf; S Modrow
Journal:  J Gen Virol       Date:  1994-06       Impact factor: 3.891

8.  Phenotypic characterization of insertion mutants of the human immunodeficiency virus type 1 Gag precursor expressed in recombinant baculovirus-infected cells.

Authors:  N Chazal; C Carrière; B Gay; P Boulanger
Journal:  J Virol       Date:  1994-01       Impact factor: 5.103

9.  Linker insertion mutations in the human immunodeficiency virus type 1 gag gene: effects on virion particle assembly, release, and infectivity.

Authors:  A S Reicin; S Paik; R D Berkowitz; J Luban; I Lowy; S P Goff
Journal:  J Virol       Date:  1995-02       Impact factor: 5.103

10.  Structures of poliovirus complexes with anti-viral drugs: implications for viral stability and drug design.

Authors:  R A Grant; C N Hiremath; D J Filman; R Syed; K Andries; J M Hogle
Journal:  Curr Biol       Date:  1994-09-01       Impact factor: 10.834

View more
  14 in total

1.  Glycine-amide is an active metabolite of the antiretroviral tripeptide glycyl-prolyl-glycine-amide.

Authors:  Elin Andersson; Peter Horal; Alenka Jejcic; Stefan Höglund; Jan Balzarini; Anders Vahlne; Bo Svennerholm
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

2.  A cell-penetrating helical peptide as a potential HIV-1 inhibitor.

Authors:  Hongtao Zhang; Qian Zhao; Shibani Bhattacharya; Abdul A Waheed; Xiaohe Tong; Anita Hong; Susanne Heck; Francesca Curreli; Michael Goger; David Cowburn; Eric O Freed; Asim K Debnath
Journal:  J Mol Biol       Date:  2008-03-06       Impact factor: 5.469

3.  Orally active antiviral tripeptide glycyl-prolyl-glycinamide is activated by CD26 (dipeptidyl peptidase IV) before transport across the intestinal epithelium.

Authors:  Ina Hubatsch; Lucia Lazorova; Anders Vahlne; Per Artursson
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

4.  Virtual screening based identification of novel small-molecule inhibitors targeted to the HIV-1 capsid.

Authors:  Francesca Curreli; Hongtao Zhang; Xihui Zhang; Ilya Pyatkin; Zagorodnikov Victor; Andrea Altieri; Asim K Debnath
Journal:  Bioorg Med Chem       Date:  2010-11-25       Impact factor: 3.641

5.  ATPgammaS disrupts human immunodeficiency virus type 1 virion core integrity.

Authors:  Cagan Gurer; Anders Höglund; Stefan Höglund; Jeremy Luban
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

6.  Antiviral compounds modulate elasticity, strength and material fatigue of a virus capsid framework.

Authors:  Santos Domínguez-Zotes; Alejandro Valbuena; Mauricio G Mateu
Journal:  Biophys J       Date:  2022-02-11       Impact factor: 4.033

7.  GPG-NH2 acts via the metabolite alphaHGA to target HIV-1 Env to the ER-associated protein degradation pathway.

Authors:  Alenka Jejcic; Stefan Höglund; Anders Vahlne
Journal:  Retrovirology       Date:  2010-03-15       Impact factor: 4.602

8.  Activity of the small modified amino acid alpha-hydroxy glycineamide on in vitro and in vivo human immunodeficiency virus type 1 capsid assembly and infectivity.

Authors:  Samir Abdurahman; Akos Végvári; Masoud Youssefi; Michael Levi; Stefan Höglund; Elin Andersson; Peter Horal; Bo Svennerholm; Jan Balzarini; Anders Vahlne
Journal:  Antimicrob Agents Chemother       Date:  2008-07-21       Impact factor: 5.191

9.  Gene expression deregulation in postnatal skeletal muscle of TK2 deficient mice reveals a lower pool of proliferating myogenic progenitor cells.

Authors:  João A Paredes; Xiaoshan Zhou; Stefan Höglund; Anna Karlsson
Journal:  PLoS One       Date:  2013-01-14       Impact factor: 3.240

10.  Biophysical characterization of the feline immunodeficiency virus p24 capsid protein conformation and in vitro capsid assembly.

Authors:  Jennifer Serrière; Daphna Fenel; Guy Schoehn; Patrice Gouet; Christophe Guillon
Journal:  PLoS One       Date:  2013-02-15       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.